DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for ovarian clear cell adenocarcinoma — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian clear cell adenocarcinoma maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian clear cell adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
kelch like ECH associated protein 1 (KEAP1) — KEAP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2r,3sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8IXS · 1.48 Å · ligand (2R,3S)-3-[[(2S)-2-fluoranyl-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanoyl]amino]-2-methyl-3-(4-methylphenyl)propanoic acid (T6I). Experimental structure, not a prediction.
What the evidence adds up to
A single case report describes a patient with recurrent and refractory ovarian clear cell carcinoma who received a combination of bevacizumab, trabectedin and oxaliplatin and achieved complete remission. The progression-free interval was over 30 months, and the patient was still receiving the therapy without toxicities above grade 2. This is a single patient, not a trial, and the abstract itself notes that clear cell carcinoma of the ovary is “exceedingly chemo-resistant,” with progression-free survival under 6 months even in patients who respond to conventional cytotoxic agents.
A separate case report describes a patient who underwent fertility-sparing surgery for Stage IA clear cell carcinoma and may have developed de novo clear cell carcinoma in the contralateral ovary 9 years later. The abstract states that a consensus is forming that fertility-sparing surgery is an option for Stage IA disease, but long-term monitoring is advised for recurrence or de novo contralateral development. No treatment outcomes are reported in this abstract.
A third report, in Indonesian, states that standard management for ovarian clear cell cancer is cytoreductive surgery followed by adjuvant carboplatin and paclitaxel chemotherapy. It notes that the cancer’s stem cell resistance and its tendency to be chemo-resistant play a role in local recurrence. Radiotherapy is described as palliative for reducing symptoms and improving quality of life, and can be given with curative intent if relapse is local; brachytherapy dose escalation may be considered for limited residual tumour. This is a case report, not a trial, and no survival or response numbers are given.
What is missing: no prospective trial has tested any of these approaches specifically in ovarian clear cell carcinoma. The bevacizumab–trabectedin–oxaliplatin combination rests on a single case. Radiotherapy data are limited to case reports with no quantified outcomes. No biomarker or molecular stratification has been validated to select patients likely to respond. Funding for a dedicated trial in this rare subtype remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of obstetrics and gynaecology research · 2012 · 14 citations
Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin
AbstractClear cell carcinoma of the ovary has shown an exceedingly chemo-resistant phenotype, especially in cases that are recurrent or refractory to previous therapy. Also, progression-free survival was less than 6 months, even in the patients that achieved response when they were treated with conventional anti-cancer cytotoxic agents. We present a case with recurrent and refractory ovarian clear cell carcinoma that achieved complete remission using a combination of bevacizumab, trabectedin and oxaliplatin. The progression-free interval of the patient is over 30 months, and she is still receiving the combination therapy without toxicities of more than grade 2.
International Cancer Conference Journal · 2016 · 2 citations · open access
Possible de novo clear cell carcinoma in the contralateral ovary 9 years after fertility-sparing surgery for Stage IA clear cell ovarian carcinoma
AbstractA patient who underwent fertility-sparing surgery for Stage IA clear cell carcinoma may have developed de novo clear cell carcinoma in the contralateral ovary 9 years later. She underwent fertility-sparing surgery and postoperative adjuvant chemotherapy for right ovarian carcinoma at 33 years of age (when endometriosis was observed in the contralateral ovary). At the age of 41 years, a tumor was discovered in the left ovary. This was diagnosed pathologically as clear cell carcinoma with clear cell adenofibroma, which may have developed de novo. A consensus is currently taking shape that although fertility-sparing surgery is a therapeutic option for patients with Stage IA clear cell carcinoma, long-term outpatient monitoring is advised to watch for its recurrence or de novo development in the contralateral ovary.
Health & Medical Journal · 2019 · 1 citations · open access
Tatalaksana Radioterapi pada Kekambuhan Lokal Kanker Ovarium Clear Cell
AbstractLatar belakang: Kanker ovarium clear cell merupakan subtype jarang ditemukan. Kanker ovarium tidak memiliki gejala pada stadium awal sehingga lebih sering ditemukan pada stadium lanjut. Tatalaksana standar adalah dengan operasi sitoreduksi dilanjutkan dengan kemoterapi adjuvant Carboplatinum dan paclitaxel. Daya tahan dari sel punca kanker dan sifat kanker ovarium clear cell yang cenderung resisten berperan dalam kekambuhan lokal. Radioterapi dapat berperan secara paliatif untuk mengurangi gejala dan meningkatkan kualitas hidup pasien. Radioterapi dapat diberikan dengan niat kuratif jika relaps terjadi secara lokal, peningkatan dosis dengan brakhiterapi dapat dipertimbangkan sebagai terapi lokal pada residu tumor terbatas. Laporan kasus: Seorang wanita berusia 34 tahun menjalani proses sectio caesarea pada kehamilan pertama aterm. Dalam durante operasi ditemukan massa berbenjol pada ovarium, sehingga diputuskan untuk dilakukan Histerek-Salphingo Oovorektomi Bilateral (HTSOB). Pemeriksaan histopatologi didapatkan jenis tumor adalah kanker ovarium clear cell. Kesimpulan: Radioterapi berperan secara palliative mengurangi gejala perdarahan, nyeri dan memperbaiki kualitas hidup pasien. Pada kanker ovarium clear cells radioterapi diberikan dengan tujuan kuratif dengan target lokal dan dapat diperttimbangkan pada kasus tertentu pemberian brakhiterapi untuk peningkatan dosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
